StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note released on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Stock Down 1.1 %

Shares of NASDAQ:NERV opened at $1.82 on Friday. The company has a market capitalization of $12.73 million, a P/E ratio of -4.14 and a beta of 0.12. Minerva Neurosciences has a 52-week low of $1.77 and a 52-week high of $9.40. The stock’s fifty day simple moving average is $2.18 and its 200-day simple moving average is $2.42.

Institutional Investors Weigh In On Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Northern Trust Corp grew its stake in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 36,878 shares of the biopharmaceutical company’s stock after buying an additional 13,829 shares during the period. Northern Trust Corp owned 0.53% of Minerva Neurosciences worth $82,000 as of its most recent SEC filing. 34.56% of the stock is owned by institutional investors and hedge funds.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.